Sier CFM - Search Results

1

A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.

Baart VM, van der Horst G, Deken MM, Bhairosingh SS, Schomann T, Sier VQ, van der Mark MH, Iamele L, de Jonge H, Resnati M, Mazar AP, Pelger RCM, van der Pluijm G, Kuppen PJK, Vahrmeijer AL, Sier CFM. Baart VM, et al. Among authors: sier vq, sier cfm. Eur J Cancer. 2021 Mar;146:11-20. doi: 10.1016/j.ejca.2021.01.001. Epub 2021 Feb 6. Eur J Cancer. 2021. PMID: 33561783 Free article.

2

Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.

Sier CF, Fellbaum C, Verspaget HW, Schmitt M, Griffioen G, Graeff H, Hôfler H, Lamers CB. Sier CF, et al. Histopathology. 1991 Sep;19(3):231-7. doi: 10.1111/j.1365-2559.1991.tb00027.x. Histopathology. 1991. PMID: 1916697

3

Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.

Verspaget HW, Sier CF, Ganesh S, Griffioen G, Lamers CB. Verspaget HW, et al. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1105-9. doi: 10.1016/0959-8049(95)00170-n. Eur J Cancer. 1995. PMID: 7577001 Review.

4

Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB, et al. Ganesh S, et al. Cancer Res. 1994 Aug 1;54(15):4065-71. Cancer Res. 1994. PMID: 8033138

5

Prognostic value of the plasminogen activation system in patients with gastric carcinoma.

Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB, Verspaget HW. Ganesh S, et al. Cancer. 1996 Mar 15;77(6):1035-43. doi: 10.1002/(sici)1097-0142(19960315)77:6<1035::aid-cncr5>3.0.co;2-g. Cancer. 1996. PMID: 8635120

6

The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.

Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F. Sier CF, et al. Cancer Res. 1998 May 1;58(9):1843-9. Cancer Res. 1998. PMID: 9581823

7

Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.

Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brünner N, Blasi F. Sier CF, et al. Lab Invest. 1999 Jun;79(6):717-22. Lab Invest. 1999. PMID: 10378514

8

Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo.

Sidenius N, Sier CF, Blasi F. Sidenius N, et al. FEBS Lett. 2000 Jun 9;475(1):52-6. doi: 10.1016/s0014-5793(00)01624-0. FEBS Lett. 2000. PMID: 10854857 Free article.

9

PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor.

Degryse B, Sier CF, Resnati M, Conese M, Blasi F. Degryse B, et al. FEBS Lett. 2001 Sep 14;505(2):249-54. doi: 10.1016/s0014-5793(01)02797-1. FEBS Lett. 2001. PMID: 11566185 Free article.

10

Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.

Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N. Sier CF, et al. Thromb Haemost. 2004 Feb;91(2):403-11. doi: 10.1160/TH03-06-0351. Thromb Haemost. 2004. PMID: 14961171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

123 results

Search Page